Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia
Journal Information
Vol. 151. Issue 2.
Pages 65-67 (July 2018)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 151. Issue 2.
Pages 65-67 (July 2018)
Brief report
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia
Significado clínico del aumento de los valores séricos de FGF-23 en la displasia fibrosa
Visits
...
Helena Floreza, Stanislava Mandelikovaa, Xavier Filellab, Ana Monegala, Núria Guañabensa, Pilar Perisa,
Corresponding author
pperis@clinic.ub.es

Corresponding author.
a Servicio de Reumatología, Unidad de Patología Metabólica Ósea, Hospital Clínic de Barcelona, CIBERehd, IDIBAPS, Universidad de Barcelona, Barcelona, Spain
b Servicio de Bioquímica y Genética Molecular, Hospital Clínic de Barcelona, Barcelona, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Clinical characteristics, laboratory parameters and therapies used in patients with fibrous dysplasia.
Abstract
Introduction and objective

Fibrous dysplasia (FD) can be associated with the development of hypophosphatemic osteomalacia, caused by the production of FGF-23 by dysplastic bone tissue. This study analysed FGF-23 levels in patients with FD, and their association with disease activity and serum phosphate values.

Patients and methods

Twelve adult patients with FD were included in the study. Clinical history, disease extension and activity and treatments received were reviewed, and the relationship of those values with FGF-23 and serum P levels was analysed.

Results

FGF-23 was elevated in 6/12 patients (50%). Patients with high FGF-23 levels had similar age and disease activity and extension than those who did not. No differences were observed in serum phosphate values between both groups (increased FGF-23: 3.9±0.9mg/dl vs. decreased FGF-23: 3.5±0.6mg/dl). In fact, none of the patients with increased FGF-23 had low serum phosphate values.

Conclusion

Adult FD patients frequently present elevated FGF-23 values with no serum phosphate level repercussion, suggesting an alteration in the processing of this protein in the dysplastic bone tissue for this pathology.

Keywords:
Fibrous dysplasia
Fibroblast growth factor 23
Resumen
Introducción y objetivo

La displasia fibrosa (DF) puede asociarse al desarrollo de osteomalacia hipofosfatémica por la producción de FGF-23 en el tejido óseo displásico. En este estudio se analizan los valores de FGF-23 en pacientes con DF y su relación con la actividad de la enfermedad y con los valores de fosfato sérico.

Pacientes y métodos

Se incluyó a 12 pacientes adultos con DF. Se revisaron las características clínicas, los parámetros analíticos y los tratamientos realizados y su relación con los valores de FGF-23.

Resultados

Seis de 12 pacientes (50%) tenían un aumento del FGF-23; estos pacientes tenían una edad, una extensión y una actividad de la enfermedad similares a aquellos con FGF-23 normal. No se observaron diferencias entre los valores de fosfato sérico entre ambos grupos (FGF-23 alto: 3,9±0,9mg/dl vs. FGF-23 normal: 3,5±0,6mg/dl). Ningún paciente con aumento de FGF-23 tenía valores de fosfato sérico bajos.

Conclusión

Los pacientes adultos con DF presentan con frecuencia un aumento del FGF-23 sin repercusión en los niveles séricos de fosfato, lo que indica una alteración en el procesamiento de esta proteína en el tejido óseo displásico en esta patología.

Palabras clave:
Displasia fibrosa
Factor de crecimiento de los fibroblastos 23

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos